Compare Dulaglutide vs Tirzepatide

The dulaglutide vs tirzepatide choice is not a universal-winner contest: both are Lilly once-weekly prescription drugs with human randomized-trial evidence. Tirzepatide activates GIP and GLP-1 receptors and produced larger A1c and weight reductions in direct trials; dulaglutide activates GLP-1 alone and offers an established single-use pen plus a labeled cardiovascular-risk indication.

What is the main difference between dulaglutide and tirzepatide?

Dulaglutide and tirzepatide differ first in mechanism: dulaglutide copies one incretin signal, GLP-1, while tirzepatide activates both GIP and GLP-1 receptors. Incretins are gut hormones that help coordinate the body’s response to food. Both drugs increase insulin release when glucose is high, reduce glucagon, slow stomach emptying, and can quiet appetite.

Dulaglutide is the molecule in Trulicity. Tirzepatide is the molecule in both Mounjaro and Zepbound. All three brands come from Eli Lilly and use weekly under-the-skin injections, but the brand names are not interchangeable shorthand for the same approved purpose: Mounjaro is the diabetes brand, while Zepbound is the weight-management and obesity-related sleep-apnea brand.

Which lowers A1c and body weight more?

Tirzepatide produced larger reductions in both A1c and body weight in direct randomized comparisons, including SURPASS-SWITCH. In that 282-person trial, adults with inadequately controlled type 2 diabetes either escalated dulaglutide or switched to tirzepatide. At week 40, A1c fell 0.67 percentage points with dulaglutide and 1.44 points with tirzepatide; weight fell 3.6 kg and 10.5 kg, respectively (SURPASS-SWITCH).

Dulaglutide was not handed an easy opponent role: the comparison escalated Trulicity toward 4.5 mg or the maximum tolerated dose. Still, the trial was open-label, involved people already taking lower-dose dulaglutide, and was funded by Lilly. Those details limit how far the averages travel. A separate double-blind trial in Japanese adults, SURPASS J-mono, also directly compared the compounds rather than asking readers to stitch together unrelated studies (PubMed).

How do their FDA approvals differ?

Dulaglutide has the narrower metabolic label but an established cardiovascular-risk indication; tirzepatide covers more distinct conditions. As of 2026, Trulicity is approved for type 2 diabetes in adults and children aged 10 and older, plus reducing major cardiovascular events in certain adults with type 2 diabetes. Trulicity is not FDA-approved for obesity (DailyMed).

Tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity (DailyMed). SURPASS-CVOT also directly compared cardiovascular outcomes in 13,299 people with type 2 diabetes and cardiovascular disease; tirzepatide was noninferior to dulaglutide for the primary cardiovascular outcome (PubMed). Noninferior means it did not perform unacceptably worse by the trial’s predefined margin, not that the drugs were identical in every respect.

Are the pens and labeled doses different?

Dulaglutide offers the simpler fixed-dose device story, although both drugs have ready-to-use approved products and require no reconstitution. Trulicity comes as a single-use pen in labeled once-weekly strengths from 0.75 mg through 4.5 mg. The pen supplies a fixed dose, which removes vial math from the job. That simplicity is a fair reason to prefer dulaglutide when the clinical goals fit.

Tirzepatide also uses once-weekly ready-to-inject presentations, including pens and single-dose vials. The label starts at 2.5 mg weekly for four weeks, then moves to 5 mg; later 2.5 mg increases may lead to maintenance doses of 5, 10, or 15 mg. These are labeled schedules, not a personal dosing plan. For broader context on this drug family, see the GLP-1 and metabolic peptide hub.

Do their side effects differ much?

Dulaglutide and tirzepatide share more safety issues than their different mechanisms might suggest. Nausea, diarrhea, vomiting, and reduced appetite appear on both labels; abdominal pain and indigestion feature on the Trulicity label, while constipation is common with tirzepatide. Gastrointestinal problems often cluster around starting treatment or raising the dose.

Dulaglutide and tirzepatide also carry boxed warnings about thyroid C-cell tumors found in rodents, with human relevance unknown. Both are contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both labels address pancreatitis, gallbladder problems, and increased hypoglycemia risk when combined with insulin or a sulfonylurea. The site’s side-effects reference explains why a shared drug class can produce a shared set of trade-offs.

Should you choose dulaglutide or tirzepatide by goal?

The dulaglutide vs tirzepatide decision makes sense only after the goal is named. For maximum additional A1c lowering and weight loss after lower-dose Trulicity, direct trial evidence favors tirzepatide. For FDA-approved chronic weight management, tirzepatide is the relevant molecule because Zepbound has that indication. Those are strong by-goal picks, not a claim that tirzepatide wins every clinical decision.

Dulaglutide fits the goal of a simple, established fixed-dose weekly pen and has a specific FDA-labeled cardiovascular-risk-reduction indication in type 2 diabetes. A prescriber weighing dulaglutide or tirzepatide also has to account for tolerance, contraindications, other medicines, coverage, and the condition being treated. The shorthand searches Trulicity vs Mounjaro and Trulicity vs Zepbound therefore ask different regulatory questions, even though Mounjaro and Zepbound contain the same molecule. Readers comparing the strength of each claim can also use the site’s evidence-grading guide.